NO991194L - Kontrollert-frigj°ring doseform av [R-(Z)-<alfa>-(metoksyimino)-<alfa>-(azabisyklo[2,2,2]okt-3-yl)acetonitril monohydroklorid - Google Patents
Kontrollert-frigj°ring doseform av [R-(Z)-<alfa>-(metoksyimino)-<alfa>-(azabisyklo[2,2,2]okt-3-yl)acetonitril monohydrokloridInfo
- Publication number
- NO991194L NO991194L NO991194A NO991194A NO991194L NO 991194 L NO991194 L NO 991194L NO 991194 A NO991194 A NO 991194A NO 991194 A NO991194 A NO 991194A NO 991194 L NO991194 L NO 991194L
- Authority
- NO
- Norway
- Prior art keywords
- alfa
- methoxyimino
- azabicyclo
- oct
- controlled
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9619074.9A GB9619074D0 (en) | 1996-09-12 | 1996-09-12 | Composition |
| PCT/GB1997/002418 WO1998010762A2 (en) | 1996-09-12 | 1997-09-08 | Controlled release dosage form of r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2oct-c-yl)acetonitrile monohydrochloride |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO991194D0 NO991194D0 (no) | 1999-03-11 |
| NO991194L true NO991194L (no) | 1999-03-11 |
Family
ID=10799833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO991194A NO991194L (no) | 1996-09-12 | 1999-03-11 | Kontrollert-frigj°ring doseform av [R-(Z)-<alfa>-(metoksyimino)-<alfa>-(azabisyklo[2,2,2]okt-3-yl)acetonitril monohydroklorid |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0929301A2 (de) |
| JP (1) | JP2001500150A (de) |
| KR (1) | KR20000036039A (de) |
| CN (2) | CN1235544A (de) |
| AR (1) | AR008176A1 (de) |
| AU (1) | AU724086B2 (de) |
| BR (1) | BR9711734A (de) |
| CA (1) | CA2265661A1 (de) |
| CO (1) | CO5031291A1 (de) |
| CZ (1) | CZ83299A3 (de) |
| GB (1) | GB9619074D0 (de) |
| HU (1) | HUP9904401A3 (de) |
| ID (1) | ID19589A (de) |
| IL (1) | IL128781A0 (de) |
| MA (1) | MA24359A1 (de) |
| NO (1) | NO991194L (de) |
| NZ (1) | NZ334268A (de) |
| PE (1) | PE2499A1 (de) |
| PL (1) | PL332074A1 (de) |
| TR (1) | TR199900505T2 (de) |
| WO (1) | WO1998010762A2 (de) |
| ZA (1) | ZA978133B (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2775597B1 (fr) * | 1998-03-04 | 2001-04-20 | Gattefosse Ets Sa | Pellet administrable par voie orale apte a ameliorer la biodisponibilite de la substance active, procede de fabrication |
| PL342600A1 (en) | 1998-03-11 | 2001-06-18 | Smithkline Beecham Plc | Composition |
| DE19918325A1 (de) * | 1999-04-22 | 2000-10-26 | Euro Celtique Sa | Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion |
| FR2796840B1 (fr) * | 1999-07-26 | 2003-06-20 | Ethypharm Lab Prod Ethiques | Comprimes faiblement doses et procede de preparation |
| US6733781B2 (en) * | 2000-12-06 | 2004-05-11 | Wyeth | Fast dissolving tablet |
| PE20040134A1 (es) | 2002-07-25 | 2004-03-06 | Pharmacia Corp | Forma de dosificacion de una vez al dia de pramipexol |
| US20060252820A1 (en) * | 2003-04-25 | 2006-11-09 | Tetsuya Suzuki | Composition for oral administration containing alkylene dioxybenzene derivative |
| US20070009596A1 (en) * | 2003-05-14 | 2007-01-11 | Bruschi Stefano D L | Controlled drug release composition resistant to in vivo mechanic stress |
| US20050142191A1 (en) * | 2003-06-23 | 2005-06-30 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
| JP2005272347A (ja) * | 2004-03-24 | 2005-10-06 | Ohara Yakuhin Kogyo Kk | 固形製剤の製造方法 |
| EP1778201B1 (de) * | 2004-08-13 | 2014-07-16 | Boehringer Ingelheim International GmbH | Pramipexolhaltige pharmazeutische pelletzusammensetzungen mit verzögerter wirkstoffabgabe, deren herstellungsverfahren und anwendung |
| PL1789021T3 (pl) | 2004-08-13 | 2012-04-30 | Boehringer Ingelheim Int | Preparat tabletkowy o przedłużonym uwalnianiu zawierający pramipeksol lub jego farmaceutycznie dopuszczalną sól |
| EP1970056A1 (de) * | 2007-03-15 | 2008-09-17 | Polichem S.A. | Zeitspezifische Dosierformen mit verzögerter/pulsatiler Freisetzung |
| US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2219636T3 (es) * | 1989-04-13 | 2004-12-01 | Beecham Group P.L.C. | Nuevos compuestos. |
| GB9409718D0 (en) * | 1994-05-14 | 1994-07-06 | Smithkline Beecham Plc | Novel compounds |
| GB9421472D0 (en) * | 1994-10-25 | 1994-12-07 | Smithkline Beecham Plc | Novel methods |
| AR004178A1 (es) * | 1995-07-29 | 1998-11-04 | Smithkline Beecham Plc | Procedimiento para la formulacion de un farmaco, una composicion farmaceutica obtenible mediante este procedimiento y el uso de la misma. |
-
1996
- 1996-09-12 GB GBGB9619074.9A patent/GB9619074D0/en active Pending
-
1997
- 1997-09-08 IL IL12878197A patent/IL128781A0/xx unknown
- 1997-09-08 WO PCT/GB1997/002418 patent/WO1998010762A2/en not_active Application Discontinuation
- 1997-09-08 HU HU9904401A patent/HUP9904401A3/hu unknown
- 1997-09-08 BR BR9711734A patent/BR9711734A/pt unknown
- 1997-09-08 JP JP10513352A patent/JP2001500150A/ja active Pending
- 1997-09-08 CZ CZ99832A patent/CZ83299A3/cs unknown
- 1997-09-08 KR KR1019997002030A patent/KR20000036039A/ko not_active Application Discontinuation
- 1997-09-08 EP EP97939064A patent/EP0929301A2/de not_active Withdrawn
- 1997-09-08 PL PL97332074A patent/PL332074A1/xx unknown
- 1997-09-08 CA CA002265661A patent/CA2265661A1/en not_active Abandoned
- 1997-09-08 CN CN97199411A patent/CN1235544A/zh active Pending
- 1997-09-08 TR TR1999/00505T patent/TR199900505T2/xx unknown
- 1997-09-08 AU AU41288/97A patent/AU724086B2/en not_active Ceased
- 1997-09-08 NZ NZ334268A patent/NZ334268A/xx unknown
- 1997-09-09 CO CO97052280A patent/CO5031291A1/es unknown
- 1997-09-10 AR ARP970104130A patent/AR008176A1/es not_active Application Discontinuation
- 1997-09-10 PE PE1997000805A patent/PE2499A1/es not_active Application Discontinuation
- 1997-09-10 MA MA24792A patent/MA24359A1/fr unknown
- 1997-09-10 ID IDP973137A patent/ID19589A/id unknown
- 1997-09-10 ZA ZA978133A patent/ZA978133B/xx unknown
-
1999
- 1999-03-11 NO NO991194A patent/NO991194L/no unknown
-
2003
- 2003-01-23 CN CN03102977A patent/CN1446535A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998010762A3 (en) | 1998-06-04 |
| NO991194D0 (no) | 1999-03-11 |
| CN1235544A (zh) | 1999-11-17 |
| CZ83299A3 (cs) | 1999-08-11 |
| CA2265661A1 (en) | 1998-03-19 |
| PL332074A1 (en) | 1999-08-30 |
| GB9619074D0 (en) | 1996-10-23 |
| BR9711734A (pt) | 1999-08-24 |
| KR20000036039A (ko) | 2000-06-26 |
| WO1998010762A2 (en) | 1998-03-19 |
| HUP9904401A2 (hu) | 2000-06-28 |
| IL128781A0 (en) | 2000-01-31 |
| CO5031291A1 (es) | 2001-04-27 |
| EP0929301A2 (de) | 1999-07-21 |
| AU4128897A (en) | 1998-04-02 |
| ID19589A (id) | 1998-07-23 |
| AU724086B2 (en) | 2000-09-14 |
| NZ334268A (en) | 2000-10-27 |
| AR008176A1 (es) | 1999-12-09 |
| PE2499A1 (es) | 1999-03-24 |
| HUP9904401A3 (en) | 2001-03-28 |
| TR199900505T2 (de) | 1999-06-21 |
| CN1446535A (zh) | 2003-10-08 |
| JP2001500150A (ja) | 2001-01-09 |
| MA24359A1 (fr) | 1998-07-01 |
| ZA978133B (en) | 1999-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO991194L (no) | Kontrollert-frigj°ring doseform av [R-(Z)-<alfa>-(metoksyimino)-<alfa>-(azabisyklo[2,2,2]okt-3-yl)acetonitril monohydroklorid | |
| KR100246065B1 (en) | Substituted 3-aminoquinuclidines | |
| UA41355C2 (uk) | Засіб для лікування нейро-сніду | |
| NO995794L (no) | Farmasoeytisk preparat inneholdende "Lactobacillus casei rhamnosus" | |
| EE04854B1 (et) | Oksabispidiinühendid, nende valmistamise meetod ning ravimvorm kasutamiseks südame arütmia raviks ja profülaktikaks | |
| NO864336L (no) | Fremgangsmaate for fremstilling av terapeutisk aktive n-substituerte-n-(3-(1,2,4-triazolo(4,3-6)pyridazin-6-yl)fenyl)alkanamider,-karbamater og -urinstoffer. | |
| MX9200361A (es) | Nuevo uso del antagonista de adenosina. | |
| DE69713151D1 (de) | Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung | |
| BG103474A (en) | Application of derivatives of 7-(2-oxa-5,8-diazobicyclo[4,3,0]non-8-8-yl)-quinoloncarboxylic acid and naphthyridoncarboxylic acid in the therapy of helicobacter pylor infections and the gastroduodenal diseases related to them | |
| MY130208A (en) | Quetiapine granules | |
| NO922426L (no) | Forbindelser med reninhemmende egenskaper, fremgangsmaate for fremstilling av disse og deres anvendelse | |
| CA2123315A1 (en) | Therapeutic agents which are antagonists or partial agonists of human interleukin 4 | |
| AU2002332488A8 (en) | R-bambuterol, its preparation and therapeutic uses | |
| NO983177L (no) | Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft | |
| MX9300927A (es) | Compuestos terapeuticos de triazina y su empleo. | |
| MXPA02006146A (es) | Uso de metabolitos bioactivos de gepirona para el tratamiento de desordenes psicologicos. | |
| TW349864B (en) | Use of N-(pyridinyl)-1H-indol-a-amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders | |
| NO910372D0 (no) | Fremgangsmaate for fremstilling av heksahydropyrrolo(2,3-b)indolkarbamater-, urea-, amider og beslektede forbindelser og deres anvendelse som medikamenter. | |
| TR199900141T2 (xx) | Bunama tedavisi ve/veya profilaksisi i�in form�lasyon. | |
| ZA931099B (en) | Heterocyclic compounds their use and preparation | |
| NO943101L (no) | 2,6-metano-2H-kinolizinderivat som 5-HT3-reseptorantagonist | |
| WO1999015160A3 (en) | Use of 6,7-substituted 2-aminotetralines suitable for preparing pharmaceutical composition for the therapeutic treatment of inflammatory and/or autoimmune pathologies | |
| PE128999A1 (es) | 1,2,4-triazolo[3,4-a]piridazina sustituida | |
| NO914654L (no) | Fremgangsmaate for fremstilling og anvendelse av beta-hydroksyetylaminer med 1,1-disubstituert cyklopropylrest | |
| KR900007413A (ko) | 에이즈 발병방지, 치료제 및 그 치료용 조성물 |